A new trading day began on Tuesday, with Esperion Therapeutics Inc (NASDAQ: ESPR) stock price down -11.67% from the previous day of trading, before settling in for the closing price of $1.20. ESPR’s price has ranged from $1.14 to $3.94 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 44.77% over the past five years. Meanwhile, its annual earnings per share averaged 83.14%. With a float of $194.37 million, this company’s outstanding shares have now reached $195.85 million.
Let’s look at the performance matrix of the company that is accounted for 304 employees. In terms of profitability, gross margin is 79.35%, operating margin of 16.37%, and the pretax margin is -15.57%.
Esperion Therapeutics Inc (ESPR) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Esperion Therapeutics Inc is 1.76%, while institutional ownership is 65.68%. The most recent insider transaction that took place on Mar 18 ’25, was worth 5,242. In this transaction Chief Financial Officer of this company sold 3,535 shares at a rate of $1.48, taking the stock ownership to the 481,710 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Commercial Officer sold 2,433 for $1.49, making the entire transaction worth $3,618. This insider now owns 370,326 shares in total.
Esperion Therapeutics Inc (ESPR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.14% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Here are Esperion Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.21 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (NASDAQ: ESPR) saw its 5-day average volume 5.2 million, a positive change from its year-to-date volume of 4.31 million. As of the previous 9 days, the stock’s Stochastic %D was 8.20%. Additionally, its Average True Range was 0.11.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 0.69%, which indicates a significant decrease from 2.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.86% in the past 14 days, which was lower than the 86.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6640, while its 200-day Moving Average is $2.0493. Nevertheless, the first resistance level for the watch stands at $1.1933 in the near term. At $1.3267, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4033. If the price goes on to break the first support level at $0.9833, it is likely to go to the next support level at $0.9067. Assuming the price breaks the second support level, the third support level stands at $0.7733.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
With a market capitalization of 209.72 million, the company has a total of 197,849K Shares Outstanding. Currently, annual sales are 332,310 K while annual income is -51,750 K. The company’s previous quarter sales were 69,110 K while its latest quarter income was -21,320 K.
